Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
AKLI Price Action
AKLI Stock Price
AKLI RSI Chart
AKLI Valuation
AKLI Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
AKLI Fundamentals
AKLI Revenue
AKLI Earnings
AKLI Profitability
AKLI Investor Care
Revenue & Growth
Revenue Breakdown
As of: Mar 31, 2024
Endeavor Otc Revenue
| |||||||||||||||
| |||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 0 | 0 | 0 | 0 |
| 2023 | 774.7K | 1.2M | 0 | 1.7M |
| 2022 | 484.3K | 430.5K | 376.8K | 323.0K |
| 2021 | 0 | 2.8M | 1.7M | 538.0K |
| 2020 | 0 | 0 | 0 | 3.9M |
Get all data in R, Python etc through our Historical Stock Data APIs
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.
| CEO | Dr. Walter Edward Martucci II, Ph.D. |
|---|---|
| WEBSITE | akiliinteractive.com |
| SECTOR | Healthcare |
| INDUSTRY | Health Information Services |
| EMPLOYEES | 111 |
